President Donald Trump announced a landmark pricing agreement with pharmaceutical giant Regeneron on Thursday, April 23, 2026. The deal makes Regeneron the 17th — and final — major drug company to join the White House’s Most-Favored-Nation (MFN) pricing initiative. Furthermore, the agreement covers all of Regeneron’s current and future drugs sold to Medicaid. This is a significant step in the Trump administration’s effort to reduce healthcare costs for millions of Americans.
What Is the Regeneron Drug Price Deal?
The Regeneron deal is a voluntary pricing agreement between the Trump administration and the drug manufacturer. Under the terms, Regeneron agrees to lower the prices of all its current and future medicines available through Medicaid. Additionally, the company will offer its cholesterol medication, Praluent, at a deeply discounted price through the government’s direct drug platform, TrumpRx. In exchange, Regeneron receives relief from pharmaceutical tariffs and other federal incentives.
Why This Deal Matters
This agreement signals the completion of a year-long effort by the Trump White House. The administration had written letters to executives of 17 major pharmaceutical companies last July. Regeneron is the last of those 17 companies to formally commit. Together, these deals now cover approximately 86% of the branded drug market in the United States. Consequently, the cumulative impact on drug affordability could be substantial.
How Most-Favored-Nation Pricing Works
Most-Favored-Nation pricing requires that American patients pay no more for a drug than the lowest price charged by any other developed nation. Currently, the US pays far more for the same medicines than countries in Europe or Asia. The MFN model directly targets this disparity. As a result, drug prices under this framework align with global benchmarks, making medicines significantly more affordable. The Trump administration argues that foreign nations have long been “free-riding” on American pharmaceutical innovation. This deal closes that gap for Regeneron’s portfolio.
Key Benefits Under the Medicaid Programme
Nationwide Access to Lower Prices
Every state Medicaid programme across the country will now gain access to MFN pricing on new Regeneron products. The White House projects hundreds of millions of dollars in combined savings. Moreover, lower drug costs directly ease the financial burden on state budgets that co-fund Medicaid. Patients on Medicaid already pay a small co-payment of a few dollars per prescription. However, lower prices improve programme sustainability and long-term affordability for the most vulnerable Americans — those with low incomes and disabilities.
Praluent Price Cut and TrumpRx Platform
Cholesterol Drug Now 58% Cheaper
One of the most immediate changes consumers will notice is a drastic price reduction on Praluent, Regeneron’s widely prescribed cholesterol-lowering medication. The drug currently costs $537. Under the new deal, patients who purchase through TrumpRx.gov will pay just $225 — a reduction of over 58%. TrumpRx launched in February 2026 as a direct-to-patient portal, allowing Americans to bypass traditional pharmacy channels and access MFN-aligned prices. Furthermore, all new Regeneron medicines coming to market will automatically receive MFN prices for US patients going forward.
Free Gene Therapy for Rare Genetic Deafness
Otarmeni Approved by FDA at No Cost
The Regeneron announcement also included a breakthrough for rare disease patients. The US Food and Drug Administration approved Otarmeni — Regeneron’s new gene therapy for a rare form of congenital genetic deafness — on the same day. This therapy treats a severe condition affecting approximately 50 children per year in the US. Importantly, Regeneron committed to providing Otarmeni at no cost to clinically eligible patients. Therefore, affected families who have long awaited treatment will not face any financial burden. The FDA approved the therapy through its Commissioner’s National Priority Voucher Programme, an expedited pathway for products aligned with critical national health priorities.
Regeneron’s $27 Billion US Investment Pledge
Beyond drug pricing, the Regeneron deal carries a significant investment commitment. The company will invest $27 billion in US research, development, and manufacturing by 2029. This includes more than doubling its domestic manufacturing capacity for biologic medicines distributed in America. The White House confirmed that this brings total pharmaceutical investment commitments under President Trump to $448 billion in just 15 months. Thus, the deal addresses both healthcare affordability and domestic manufacturing growth simultaneously.
The Broader Most-Favored-Nation Initiative
17 Companies, One Policy Goal
The Regeneron agreement is part of a series of MFN deals the Trump administration has struck since late 2025. Companies now signed onto the initiative include Pfizer, AstraZeneca, Eli Lilly, Novo Nordisk, Amgen, Bristol Myers Squibb, Gilead Sciences, GSK, Merck, Novartis, Sanofi, Johnson & Johnson, AbbVie, and others. Collectively, these agreements cover 86% of branded pharmaceuticals for the American market. President Trump and Health Secretary Robert F. Kennedy Jr. have urged Congress to codify these deals into binding law. Additionally, a US-UK agreement struck in December 2025 raised UK drug prices by 25%, ensuring that foreign nations pay their fair share for innovative medicines
What Critics and Democrats Are Saying
Not everyone views the deals positively. Democratic lawmakers have pressed the administration to publicly release the full details of every agreement. They argue that the deals fall short of the grand promises made to American voters. Moreover, some agreements have already hit roadblocks. A key provision of the deals with weight-loss drugmakers Eli Lilly and Novo Nordisk fell apart this week after Medicare delayed implementation of a coverage programme for GLP-1 medications. Critics also note that the Commissioner’s National Priority Voucher Programme — used to fast-track Otarmeni’s approval — was not authorized by Congress, raising concerns about executive overreach.
What This Means for Medicaid Patients
Relief for Low-Income Americans
For Medicaid beneficiaries, this deal offers meaningful relief. State programmes will access lower drug prices, which reduces overall programme costs. Lower spending on drugs allows states to redirect funding toward other healthcare services. Furthermore, patients who use the TrumpRx platform directly benefit from the steep discounts negotiated under MFN pricing. Over time, a broader range of affordable medicines will become available. This deal, therefore, is not only a political milestone but also a concrete step toward more equitable drug access for America’s most vulnerable populations.
